CY1122012T1 - Ενωσεις ως ρυθμιστες του ror γαμμα - Google Patents

Ενωσεις ως ρυθμιστες του ror γαμμα

Info

Publication number
CY1122012T1
CY1122012T1 CY20191100942T CY191100942T CY1122012T1 CY 1122012 T1 CY1122012 T1 CY 1122012T1 CY 20191100942 T CY20191100942 T CY 20191100942T CY 191100942 T CY191100942 T CY 191100942T CY 1122012 T1 CY1122012 T1 CY 1122012T1
Authority
CY
Cyprus
Prior art keywords
compounds
regulators
ror gamma
formula
present
Prior art date
Application number
CY20191100942T
Other languages
English (en)
Inventor
Johanna Bakonyi
Steven Richard Brunette
Delphine Collin
Robert Owen Hughes
Xiang Li
Shuang Liang
Robert Sibley
Michael Robert Turner
Lifen Wu
Qiang Zhang
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of CY1122012T1 publication Critical patent/CY1122012T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

Η παρούσα εφεύρεση εμπερικλείει ενώσεις του τύπου (I) όπου οι μεταβλητές ορίζονται στο παρόν οι οποίες είναι κατάλληλες για την ρύθμιση του RORγ και την αντιμετώπιση νόσων οι οποίες σχετίζονται με την ρύθμιση του RORγ. Η παρούσα εφεύρεση επίσης εμπερικλείει διαδικασίες παρασκευής ενώσεων του τύπου (I) και φαρμακευτικών παρασκευασμάτων τα οποία τις περιέχουν.
CY20191100942T 2014-04-14 2019-09-09 Ενωσεις ως ρυθμιστες του ror γαμμα CY1122012T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461979231P 2014-04-14 2014-04-14
PCT/US2015/025328 WO2015160654A1 (en) 2014-04-14 2015-04-10 Compounds as modulators of ror gamma

Publications (1)

Publication Number Publication Date
CY1122012T1 true CY1122012T1 (el) 2020-10-14

Family

ID=52998264

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100942T CY1122012T1 (el) 2014-04-14 2019-09-09 Ενωσεις ως ρυθμιστες του ror γαμμα

Country Status (36)

Country Link
US (5) US9242989B2 (el)
EP (2) EP3418280B1 (el)
JP (2) JP6282759B2 (el)
KR (2) KR102410069B1 (el)
CN (3) CN106132965B (el)
AP (1) AP2016009403A0 (el)
AR (2) AR100058A1 (el)
AU (2) AU2015247983B2 (el)
BR (2) BR122020020657B1 (el)
CA (1) CA2944787C (el)
CL (1) CL2016002421A1 (el)
CY (1) CY1122012T1 (el)
DK (1) DK3131902T3 (el)
EA (2) EA031351B1 (el)
ES (1) ES2744299T3 (el)
HK (2) HK1244801A1 (el)
HR (1) HRP20191579T1 (el)
HU (1) HUE045847T2 (el)
IL (2) IL247419B (el)
LT (1) LT3131902T (el)
MA (1) MA46373A (el)
ME (1) ME03513B (el)
MX (1) MX370780B (el)
MY (1) MY182834A (el)
NZ (1) NZ723530A (el)
PE (2) PE20211002A1 (el)
PH (2) PH12016502019A1 (el)
PL (1) PL3131902T3 (el)
PT (1) PT3131902T (el)
RS (1) RS59170B1 (el)
SG (1) SG11201608537SA (el)
SI (1) SI3131902T1 (el)
TW (2) TWI652268B (el)
UA (2) UA120094C2 (el)
UY (1) UY36077A (el)
WO (1) WO2015160654A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242989B2 (en) * 2014-04-14 2016-01-26 Boehringer Ingelheim International Gmbh Compounds as modulators of RORγ
FR3030518B1 (fr) * 2014-12-19 2018-03-23 Galderma Research & Development Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
EP3294713B1 (en) 2015-05-15 2021-02-17 Aurigene Discovery Technologies Limited Substituted tetrahydroquinolinone compounds as ror gamma modulators
EP3356366B1 (en) 2015-10-01 2019-08-28 Boehringer Ingelheim International GmbH Pteridine derivatives as modulators of ror gamma
EP3390396B1 (en) 2015-12-15 2022-07-06 Astrazeneca AB Isoindole compounds
US11358967B2 (en) 2016-01-20 2022-06-14 Boehringer Ingelheim International Gmbh Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma
UY37507A (es) 2016-12-05 2018-06-29 Lead Pharma Holding Bv Moduladores de ror gamma (ror¿)
US20200031753A1 (en) 2017-04-06 2020-01-30 Boehringer Ingelheim International Gmbh Cyclopropyl alkyl amines and process for their preparation
WO2018229155A1 (en) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN109206346A (zh) * 2017-07-01 2019-01-15 复旦大学 叔胺类衍生物或其盐及其制备方法和用途
CN107903263B (zh) * 2017-12-28 2019-11-12 山东铂源药业有限公司 一种帕布昔利布中间体的合成方法
MX2020011405A (es) 2018-05-03 2021-01-08 Jiangsu Hengrui Medicine Co Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
EP3867224A1 (en) 2018-10-18 2021-08-25 Boehringer Ingelheim International GmbH Scalable synthesis of optically active 1-cyclopropylalkyl-1-amines
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
TW202118751A (zh) 2019-10-31 2021-05-16 大陸商江蘇恒瑞醫藥股份有限公司 RORγ調節劑的酸加成鹽
WO2022106547A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Process for synthesising a ror gamma inhibitor
WO2022106549A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline salts of a ror gamma inhibitor
WO2022106551A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Co-crystals of a ror gamma inhibitor
WO2022106548A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Solid forms of a ror gamma inhibitor
WO2022106550A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline polymorphic form of a ror gamma inhibitor
CN117003757A (zh) * 2022-05-07 2023-11-07 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为usp1抑制剂
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
WO2009022185A2 (en) * 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
UA103634C2 (en) 2008-09-26 2013-11-11 Берингер Ингельхайм Интернациональ Гмбх Azaindazole compounds as ccr1 receptor antagonists
IN2012DN03449A (el) 2009-10-21 2015-10-23 Boehringer Ingelheim Int
JP6093759B2 (ja) * 2011-06-01 2017-03-08 ジャナス バイオセラピューティクス，インク． 新規の免疫系調節剤
WO2013170671A1 (zh) * 2012-05-14 2013-11-21 华东理工大学 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
US9242989B2 (en) * 2014-04-14 2016-01-26 Boehringer Ingelheim International Gmbh Compounds as modulators of RORγ
EP3356366B1 (en) * 2015-10-01 2019-08-28 Boehringer Ingelheim International GmbH Pteridine derivatives as modulators of ror gamma
US11358967B2 (en) * 2016-01-20 2022-06-14 Boehringer Ingelheim International Gmbh Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma

Also Published As

Publication number Publication date
US20150291607A1 (en) 2015-10-15
AP2016009403A0 (en) 2016-08-31
MY182834A (en) 2021-02-05
EA201890329A1 (ru) 2018-07-31
MX2016013342A (es) 2017-01-26
PH12016502019B1 (en) 2017-01-09
CA2944787C (en) 2023-03-14
HUE045847T2 (hu) 2020-01-28
EA035063B1 (ru) 2020-04-23
EP3131902B1 (en) 2019-06-12
US20160075706A1 (en) 2016-03-17
JP6282759B2 (ja) 2018-02-21
UY36077A (es) 2015-10-30
LT3131902T (lt) 2019-09-25
AU2019203027B2 (en) 2020-07-09
ES2744299T3 (es) 2020-02-24
TW201841915A (zh) 2018-12-01
PE20211002A1 (es) 2021-06-01
CA2944787A1 (en) 2015-10-22
PH12020500252A1 (en) 2021-07-26
JP2017511357A (ja) 2017-04-20
SG11201608537SA (en) 2016-11-29
AU2015247983A1 (en) 2016-09-08
AR100058A1 (es) 2016-09-07
BR112016021962B1 (pt) 2022-12-13
JP6463855B2 (ja) 2019-02-06
US20180022749A1 (en) 2018-01-25
RS59170B1 (sr) 2019-10-31
EP3131902A1 (en) 2017-02-22
US20190002465A1 (en) 2019-01-03
US20170008894A1 (en) 2017-01-12
BR122020020657B1 (pt) 2022-12-20
CN107266454B (zh) 2019-08-09
IL263878B (en) 2019-11-28
HK1244801A1 (zh) 2018-08-17
HK1244800A1 (zh) 2018-08-17
UA120094C2 (uk) 2019-10-10
BR112016021962A2 (pt) 2023-01-20
IL247419B (en) 2019-03-31
IL263878A (en) 2019-01-31
SI3131902T1 (sl) 2019-10-30
US9242989B2 (en) 2016-01-26
CN107266450B (zh) 2020-07-24
AR119454A2 (es) 2021-12-22
EA031351B1 (ru) 2018-12-28
NZ723530A (en) 2023-05-26
PH12016502019A1 (en) 2017-01-09
CN106132965A (zh) 2016-11-16
DK3131902T3 (da) 2019-09-02
CL2016002421A1 (es) 2017-03-24
MA46373A (fr) 2019-08-07
CN107266454A (zh) 2017-10-20
AU2019203027A1 (en) 2019-05-23
HRP20191579T1 (hr) 2019-11-29
EP3418280B1 (en) 2023-07-12
KR102410076B1 (ko) 2022-06-22
ME03513B (me) 2020-04-20
EP3418280A1 (en) 2018-12-26
KR20200040917A (ko) 2020-04-20
AU2015247983B2 (en) 2019-05-16
CN106132965B (zh) 2020-02-07
EA201691978A1 (ru) 2017-02-28
TW201625622A (zh) 2016-07-16
KR20160142396A (ko) 2016-12-12
US9598415B2 (en) 2017-03-21
JP2018065874A (ja) 2018-04-26
UA121255C2 (uk) 2020-04-27
PL3131902T3 (pl) 2019-11-29
TWI655192B (zh) 2019-04-01
TWI652268B (zh) 2019-03-01
PE20161572A1 (es) 2017-02-01
MX370780B (es) 2020-01-03
CN107266450A (zh) 2017-10-20
PT3131902T (pt) 2019-09-17
KR102410069B1 (ko) 2022-06-20
WO2015160654A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
CY1122012T1 (el) Ενωσεις ως ρυθμιστες του ror γαμμα
CY1123853T1 (el) Ρυθμιστες nrf2
CY1124749T1 (el) Παραγωγα διπυραζολιου χρησιμα για την θεραπεια αυτοανοσων νοσηματων
CY1123598T1 (el) Μακροκυκλικα πεπτιδια χρησιμα ως ανοσοδιαμορφωτες
CY1124595T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
CY1121571T1 (el) Ανοσορρυθμιστες
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CY1120893T1 (el) Μεθοδοι για αγωγη μολυνσεων ιου filoviridae
MD3582853T2 (ro) Compuși di-nucleotidici ciclici pentru tratamentul cancerului
CY1123417T1 (el) Παραγωγα τετρα�δροϊσοκινολινης
CY1123354T1 (el) Συνθεσεις τοπικης εφαρμογης που περιλαμβανουν ενα κορτικοστεροειδες και ενα ρετινοειδες για τη θεραπεια της ψωριασης
BR112018072663A2 (pt) moduladores da via integrada ao estresse
CY1123031T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
CY1122613T1 (el) Παραγωγα 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινης ως ρυθμιστες toy gpr139
BR112017010177A2 (pt) composição para tratamento de tecido
CY1123574T1 (el) Αντιπολλαπλασιαστικες ενωσεις και φαρμακευτικες συνθεσεις και χρησεις αυτων
CL2019003515A1 (es) Compuestos heteroaromáticos como inhibidores de vanina.
CL2020000085A1 (es) Moduladores de nlrp3.
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
DOP2021000021A (es) Compuestos heteroaromáticos como inhibidores de vanina
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CY1124308T1 (el) Παραγωγα πυραζολυλαμινοβενζιμιδαζολης ως αναστολεις της jak
EA202090283A1 (ru) Модуляторы nlrp3